Identifying natural derived upregulators of human ApoA-I expression via a cell-based drug screening system

Pharmaceutical Biology

Volumn 46, Issue 9, 2008, Pages 610-615

  Deng, Ting ^a,b   Ji, Wei ^a   Lian, Ji Hong ^a   Guo, Lei ^a   Hu, Wei Rong ^a   Qian, Ming ^a   Gong, Bang Qiang ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Shanghai Guoqiang Bioengineering Equipment Co Ltd   (China)

Author keywords

ApoA I; Baicalein; Drug screening; HDL; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; BAICALEIN; CHINESE DRUG; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LUCIFERASE; NEOMYCIN;

ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CHINESE HERB; CHOLESTEROL TRANSPORT; DRUG SCREENING; DRUG STRUCTURE; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SCUTELLARIA BAICALENSIS;

LAMIACEAE; SCUTELLARIA; SCUTELLARIA BAICALENSIS;

EID: 51649115141     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200802179584     Document Type: Article

References (30)

1. Assmann G, Eckardstein AV, Brewer HB (2001): The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York, McGraw-Hill, pp. 2937-2980.
2. Brinton EA, Eisenberg S, Breslow JL (1989): Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 84: 262-269.
3. Brinton EA, Eisenberg S, Breslow JL (1990): A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 85: 144-51.
4. Brouillette CG, Anantharamaiah GM, Anglers JA, Borhani DW (2001): Structural models of human apolipoprotein A-I: A critical analysis and review. Biochim Biophys Acta 1531: 4-46.
5. Chong KS, Nicolosi RJ, Rodger RF, Arrigo DA, Yuan RW, MacKey JJ, Georas S, Herbert PN (1987): Effect of dietary fat saturation on plasma lipoproteins and high density lipoprotein metabolism of the rhesus monkey. J Clin Invest 79: 675-683.
6. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fievet C, Fielding CJ, Fielding PE (1995): Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211-228.
7. Forte TM, McCall MR (1994): The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis. Curr Opin Lipidol 5: 354-364.
8. Fruchart JC, Duriez P (1998): High density lipoproteins and coronary heart disease. Future prospects in gene therapy. Biochimie 80: 167-72.
9. Fruchart JC, Houdebine LM, Denefle P (1996): Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94: 713-717.
10. Gordon T, Kannel WB, Castelli WP, Dawber TR (1981): Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 141: 1128-1131.
11. Hsu SL, Hsieh YC, Hsieh WC, Chou CJ (2001): Baicalein induces a dual growth arrest by modulating multiple cell cycle regulatory molecules. Eur J Pharmacol 425: 165-171.
12. Huanga Y, Tsanga SY, Yaoa XQ, Chenb ZY (2005): Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 5: 177-184.
13. Kwiterovich PO (1998): The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82: 13Q-21Q.
14. LeBoeuf RC, Doolittle MH, Montcalm A, Martin DC, Reue K, Lusis AJ (1990): Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. J Lipid Res 31: 91-101.
15. Linsel-Nitschke P, Tall AR (2005): HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4: 193-205.
16. Parks JS, Rudel LL (1982): Different kinetic fates of apolipoproteins A-I and A-II from lymph chylomicra of nonhuman primates. Effect of saturated versus polyunsaturated dietary fat. J Lipid Res 23: 410-421.
17. Rubin EM, Ishida BY, Clift SM, Krauss RM (1991): Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-l and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 88: 434-438.
18. Sambrook J, Russell DW (2001): Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, pp: 1361-1362.
19. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB Jr (1982): Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23: 850-862.
20. Shah PK (2003): Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. Rev Cardiovasc Med 4: 136-141.
21. Shen YC, Chiou WF, Chou YC, Chen CFu (2003): Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol 465: 171-181.
22. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD (1978): Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I. J Clin Invest 61: 1582-1592.
23. Sirtori CR (2004): New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target. Int Congr Ser 1262: 9-14.
24. Tall AR (1990): Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 86: 379-384.
25. Thomas MS, Kearns MW (1991): Transcriptional regulation of the apolipoprotein A-I gene, species-specific expression correlates with rates of gene transcription. J Biol Chem 266: 18045-18050.
26. Thomas MS, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL (1989): Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: Relationship to plasma concentration of high density lipoproteins. J Lipid Res 30: 1397-1403.
27. Waddington EI, Boadu E, Francis GA (2005): Cholesterol and phospholipids efflux from cultured cells. Methods 36: 196-206.
28. Wang N, Silver DL, Thiele C, Tall AR (2001): ATP-binding Cassette Transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 276: 23742-23747.
29. Woo KS, Chook C, Raitakari OT, McQuillan B, Feng JZ, Celermajer DS (1999): Westernization of Chinese adults and increased subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 19: 2487-2493.
30. Zheng XL, Matsubara S, Diao C, Hollenberg MD, Wong NCW (2000): Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1. J Biol Chem 275: 31747-31754.